Exome Asset Management LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 119.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 43,849 shares of the biotechnology company's stock after buying an additional 23,849 shares during the period. Ascendis Pharma A/S makes up approximately 4.4% of Exome Asset Management LLC's holdings, making the stock its 2nd largest holding. Exome Asset Management LLC owned about 0.07% of Ascendis Pharma A/S worth $6,547,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Signaturefd LLC grew its stake in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 80 shares during the last quarter. Profund Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock valued at $398,000 after purchasing an additional 85 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 143 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S in the 3rd quarter valued at approximately $30,000. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock valued at $11,717,000 after acquiring an additional 228 shares during the last quarter.
Shares of Ascendis Pharma A/S stock opened at $129.87 on Friday. The business has a 50-day moving average price of $129.15 and a 200 day moving average price of $132.68. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The firm has a market cap of $7.88 billion, a P/E ratio of -16.07 and a beta of 0.67.
Several research firms have commented on ASND. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. decreased their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 23rd. Stifel Nicolaus raised their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Oppenheimer cut their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research note on Friday, November 15th. Finally, Evercore ISI lifted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $191.77.
Read Our Latest Research Report on Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.